The role of the interleukin-23/Th17 pathway in cardiometabolic comorbidity associated with psoriasis
Egeberg, A. (Gentofte Hospital)
Gisondi, Paolo (University of Verona)
Carrascosa, José Manuel (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol)
Warren, R. B. (Manchester NIHR Biomedical Research Centre)
Mrowietz, Ulrich (University Medical Center Schleswig-Holstein)
Universitat Autònoma de Barcelona

Data:	2020
Resum:	Alterations in the innate and adaptive immunity underpin psoriasis pathophysiology, with the Th17 cells subset now recognized as the fundamental cells in the key controlling pathway involved in its pathogenesis. Since psoriasis is a systemic disease with important comorbidity, further knowledge on the interleukin ()-23/Th17 axis led to the hypothesis that there may be shared pathogenic pathways between primary skin disease and comorbidity. Psoriasis has been identified as a risk factor for cardiovascular and metabolic disease, and increasing evidence gives support to this epidemiological observation from the clinical-pathologically field. As an example, increased levels of -23 and -23R have been found in human atherosclerotic plaque, and levels correlated with symptom duration and mortality. Also, upregulation of -23/-17 seems to play an important role in both myocardial damage and stroke, with interesting reports on deleterious effect neutralization after administration of related anti-bodies in both associated conditions. In diabetic patients, increased levels of -23/-17 have also been observed and available data support a synergistic role of -23/-17 in β-cells damage. In obesity, signs of an expansion of Th17 subset in adipose tissue have been reported, as well as elevated concentrations of -23 in obese patients. In non-alcoholic fatty liver disease, closely related to metabolic syndrome, but also in other mentioned cardiometabolic disorders, a predominance of -23 and other related pro-inflammatory factors has been identified as participating in their pathogenesis. Thus, the involvement of the -23/Th17 axis in these shared psoriasis-cardiometabolic pathogenic mechanisms is reviewed and discussed in the light of the existing preclinical and clinical evidence, including that from comorbid psoriasis patients.
Nota:	Altres ajuts: This publication was funded by Almirall R&D, Barcelona.
Drets:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original.
Llengua:	Anglès
Document:	Article ; recerca ; Versió publicada
Matèria:	Cytokines ; Humans ; Immunology ; Interleukin-17 ; Interleukin-23 ; Psoriasis ; Th17 Cells
Publicat a:	Journal of the European Academy of Dermatology and Venereology, Vol. 34 (march 2020) , p. 1695-1706, ISSN 1468-3083

DOI: 10.1111/jdv.16273
PMID: 32022950

12 p, 1.1 MB

El registre apareix a les col·leccions:
Documents de recerca > Documents dels grups de recerca de la UAB > Centres i grups de recerca (producció científica) > Ciències de la salut i biociències > Institut d'Investigació en Ciencies de la Salut Germans Trias i Pujol (IGTP)
Articles > Articles de recerca
Articles > Articles publicats